GlassScriptPhysician profile
Jigar M Patel
NPI 1174967970
$12,710.35
in general payments reported to CMS, 2019-2025
34 companies · $2,310 in 2025
The $2,310 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $326 · 2021: $839 · 2022: $1,244 · 2023: $5,546 · 2024: $1,657 · 2025: $2,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,475 · Honoraria: $4,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,474.71 |
| Honoraria | $4,037.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $4,037.50 | 2023 | Myrisk, Genesight |
| Abbvie INC. | $2,571.88 | 2019-2025 | |
| Boston Scientific Corporation | $877.61 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $722.94 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $544.95 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $472.62 | 2020-2025 | |
| Janssen Biotech, INC. | $412.85 | 2022-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $376.86 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $279.28 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $249.86 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $201.45 | 2022-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $193.54 | 2022-2023 | |
| Redhill Biopharma INC. | $184.28 | 2021-2025 | Talicia |
| Ardelyx, INC. | $177.27 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $132.66 | 2024-2025 | Zenpep |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $131.88 | 2024-2025 | |
| Vyne Pharmaceuticals INC. | $122.75 | 2021 | |
| Intercept Pharmaceuticals, INC. | $120.18 | 2019-2023 | Ocaliva |
| Lilly USA, LLC | $110.26 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $93.28 | 2022-2024 | |
| Conmed Corporation | $91.29 | 2023-2025 | Conmed Biliary, Conmed Hemostasis, Conmed Biopsy |
| Aries Pharmaceuticals, INC. | $90.29 | 2019 | |
| Madrigal Pharmaceuticals | $74.56 | 2024-2025 | Rezdiffra, Resmetirom |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.28 | 2020 | |
| Evoke Pharma, INC. | $57.86 | 2023-2024 | Gimoti |
| Esperion Therapeutics, INC. | $57.51 | 2024-2025 | Nexletol |
| Echosens North America, INC. | $56.64 | 2025 | Fibroscan |
| Concordia Pharmaceuticals INC. | $52.83 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $38.42 | 2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $26.54 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $21.59 | 2023 | Sutab |
| Alcresta Therapeutics, INC. | $20.37 | 2024 | Relizorb |
| Novo Nordisk INC | $18.14 | 2025 | Wegovy |
| Vivus LLC | $16.13 | 2025 | Pancreaze |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jigar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.